Search Results

3X4 Genetics, leader in the field of genetics-based health, announced a partnership with The Metabolic Terrain Institute of Health to serve as the innovative nonprofit’s genetics provider.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics (ACMG), published a new study validating RiskScore®, Myriad’s breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test.

Regeneron, Akouos and Mass Eye and Ear are testing therapies that can reverse genetic protein deficiency to restore hearing, with promising early results.

Experts say the time is now to develop and provide widespread access to genetic medicines for the rarest diseases. What’s more, they say it is a moral imperative.

23andMe Holding Co., a leading human genetics and biopharmaceutical company, released a new genetic Bipolar Disorder report for 23andMe+ Premium members, informing them if they are at higher likelihood for being diagnosed with the condition.

SOPHiA GENETICS, a cloud-native healthcare technology company and a leader in data-driven medicine, announced that Kepler Uniklinikum, Austria’s second largest hospital, is live on SOPHiA GENETICS’ platform.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced the addition of a new Universal Plus Panel to its Foresight® Carrier Screen.

Veritas will have a prominent presence at the upcoming European Society of Human Genetics Congress 2024, to be held in Berlin from June 1 to 4.

SOPHiA GENETICS, a cloud-native healthcare technology company and a global leader in data-driven medicine, announced its new Residual Acute Myeloid Application.